Cite
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.
MLA
Innes, A. J., et al. “Escalating-Dose HLA-Mismatched DLI Is Safe for the Treatment of Leukaemia Relapse Following Alemtuzumab-Based Myeloablative Allo-SCT.” Bone Marrow Transplantation, vol. 48, no. 10, Oct. 2013, pp. 1324–28. EBSCOhost, https://doi.org/10.1038/bmt.2013.69.
APA
Innes, A. J., Beattie, R., Sergeant, R., Damaj, G., Foroni, L., Marin, D., Kanfer, E., Mielke, S., Milojkovic, D., MacDonald, D., Pavlu, J., Rahemtulla, A., Roberts, I., Slade, D., Bray, E., Goldman, J., Apperley, J., Szydlo, R., Dazzi, F., & Rezvani, K. (2013). Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. Bone Marrow Transplantation, 48(10), 1324–1328. https://doi.org/10.1038/bmt.2013.69
Chicago
Innes, A J, R Beattie, R Sergeant, G Damaj, L Foroni, D Marin, E Kanfer, et al. 2013. “Escalating-Dose HLA-Mismatched DLI Is Safe for the Treatment of Leukaemia Relapse Following Alemtuzumab-Based Myeloablative Allo-SCT.” Bone Marrow Transplantation 48 (10): 1324–28. doi:10.1038/bmt.2013.69.